XOMA Royalty Corp files DEFA14A

This supplemental proxy filing (DEFA14A) from XOMA Royalty Corporation announces the expected closing date of its acquisition by Ligand Pharmaceuticals Incorporated and the redemption of its preferred stock. Shareholders of XOMA common stock will also receive contingent value rights (CVRs) as additional merger consideration.